Introduction
Cannabidiol is today one of the most studied plant molecules in the world. In 2026, the PubMed database already lists more than a thousand scientific publications mentioning cannabidiol, across all types of work: fundamental research, cell model studies, clinical trials, review articles, and regulatory assessments.
This volume is impressive. Yet it conceals a reality that researchers themselves consistently point out: the literature remains heterogeneous, largely preclinical, and the mechanisms of action of cannabidiol are still not fully understood.
As a Swiss laboratory specialising in hemp, TheGreenLab follows this literature closely — not to draw commercial arguments from it, which Swiss law clearly prohibits, but because understanding the true state of knowledge is part of our work. This article offers a factual overview of what research is publishing in 2026, the limitations that authors themselves acknowledge, and the regulatory framework governing the sale of hemp products in Switzerland and Europe.
A rapidly growing body of publications
Scientific output dedicated to cannabidiol has been following an upward curve for around ten years. This growth is driven by several converging factors: the gradual opening of legal frameworks in many countries, the availability of standardised extracts for research purposes, and academic interest in the endocannabinoid system discovered in the 1990s.
These figures should, however, be read carefully. A scientific publication is not necessarily a clinical trial. Within the total recorded, you will find:
- in vitro studies, conducted on cell lines in a laboratory;
- animal model studies, primarily on rodents;
- clinical trials, considerably fewer in number, and often involving small sample sizes;
- review articles, which compile and analyse existing work without generating new data;
- regulatory assessments conducted by public agencies.
This hierarchy matters. A result obtained on isolated cells does not translate mechanically to humans, and the gap between the two is one of the points most regularly raised in the literature.
A recent review article: August 2026
Among recent publications, a review published on 6 August 2026 in the journal Pharmaceuticals (volume 19, issue 8, article 1238) offers a useful overview. Authored by Șolea and co-authors, it compiles available preclinical and clinical data on cannabidiol within the field of neurological and psychiatric research.
What the review describes
The work is narrative in nature: the authors bring together the existing literature, describe its findings, and discuss how robust they are. They focus in particular on the molecular targets studied in fundamental research. Cannabidiol is described as a molecule that interacts with a range of receptors and cellular pathways: indirect modulation of CB1 and CB2 cannabinoid receptors, interaction with serotonergic 5-HT1A receptors, vanilloid receptors TRPV1 and TRPV2, nuclear receptors PPARγ, as well as orphan receptors GPR55 and GPR18.
This multiplicity of targets is in itself a notable characteristic of the molecule, and it explains why it attracts so many research teams.
What the review concludes
This is the most instructive part. The authors put forward a cautious conclusion: “many of the available studies are preclinical or involve small patient populations, and the underlying mechanisms remain incompletely understood.” They explicitly call for well-designed, randomised, controlled, multicentre trials before any generalisation can be made.
In other words: a review article published in 2026 in a scientific journal concludes that the research has not yet reached maturity. That is information in itself, and it deserves to be reported as faithfully as any positive result.
Methodological limitations acknowledged by researchers
Beyond this specific review, several limitations recur consistently across the 2026 literature.
Often small sample sizes
Many clinical trials published this year involve only a few dozen participants — sometimes fewer than twenty. Some include no placebo group. Others are conducted on healthy volunteers rather than on the populations of interest. These conditions do not invalidate the work, but they significantly limit the scope of the conclusions.
Heterogeneous protocols
Administered doses, formulations, routes of administration, and follow-up durations vary considerably from one study to the next. This heterogeneity complicates comparisons and makes meta-analyses difficult to carry out.
A complex pharmacokinetic profile
The authors of the August 2026 review emphasise an important technical point: cannabidiol has low and variable oral bioavailability, due to significant first-pass hepatic metabolism. It is metabolised in particular by the enzymes CYP2C19 and CYP3A4, and its elimination half-life varies considerably depending on the route of administration.
This has a direct consequence: cannabidiol can inhibit several cytochrome P450 enzymes, which raises the possibility of drug interactions. The authors draw particular attention to situations where other substances with a narrow safety margin are administered at the same time. Anyone following medical treatment should speak to a healthcare professional before consuming a product containing cannabidiol.
The European regulatory dimension: the EFSA opinion
2026 has also seen a significant regulatory development at European level. In February 2026, the European Food Safety Authority (EFSA) published an updated opinion on cannabidiol within the framework of the European novel food regulation.
EFSA established a provisional safe daily intake level of 0.0275 mg of cannabidiol per kilogram of body weight, equivalent to approximately 2 mg per day for a 70 kg adult. This level comes with strict conditions: it applies only to healthy adults aged 25 and over, for food supplements containing cannabidiol at a purity of 98% or above, without nanoparticles. It does not apply to people under 25, pregnant or breastfeeding women, or those taking medication.
The agency also confirmed the knowledge gaps it had already identified in 2022, relating to the pharmacokinetics of cannabidiol and its long-term effects on the liver, nervous system, reproductive system, and immune system. It indicates that a reassessment will take place as new toxicological and clinical data become available.
Important note: this opinion falls within the European food product framework. Switzerland has its own regulatory framework, and the hemp products sold by TheGreenLab are not sold as food products.
The Swiss framework: what a CBD retailer can and cannot say
In Switzerland, products containing cannabidiol with a THC content below 1% are legal and intended for an adult audience. Their sale is governed by the Therapeutic Products Act (TPA) and by legislation on foodstuffs and everyday products, under the supervision of cantonal chemists.
The principle is straightforward and far-reaching: a product that claims a health effect becomes, in law, a therapeutic product, subject to a demanding authorisation process with Swissmedic. A retailer who attributed an effect on a condition, symptom, or bodily function to their products would therefore risk having the product reclassified — along with the corresponding penalties.
That is why you will find no promised effects, no dosage guidance, and no health recommendations on thegreenlab.ch. Our product pages describe what we control and what can be verified: the origin of the raw material, the extraction method, the extract spectrum, the aromatic profile, the analysed concentrations, and batch traceability.
The distinction from the medical field is also clear in practice: in several countries, a cannabidiol-based medication exists that is authorised on prescription for specific indications in epileptology, with a marketing authorisation file, a defined dosage, and medical supervision. This is an entirely different regulatory status from that of consumer hemp products, and the two should never be conflated.
How to read information about CBD
This subject generates a great deal of content, of varying quality. A few simple habits will help you sort through it:
Offer valid for first orders only. Promo code cannot be combined with other discounts. By signing up, you agree to create a customer account and accept our privacy policy.
